aminosalicylic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2050	65-49-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aminosalicylic acid resin complex potassium aminosalicylate p-aminosalicylic acid aminosalicylic acid 4-Aminosalicylic acid 4-Carboxy-3-hydroxyaniline apacil calcium aminosalicylate sodium aminosalicylate para-aminosalicylic acid aminosalicylate potassium aminosalicylate sodium teebacin	An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid. Molecular weight: 153.14 Formula: C7H7NO3 CLOGP: 1.06 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 83.55 ALOGS: -1.11 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

aminosalicylic acid resin complex
potassium aminosalicylate
p-aminosalicylic acid
aminosalicylic acid
4-Aminosalicylic acid
4-Carboxy-3-hydroxyaniline
apacil
calcium aminosalicylate
sodium aminosalicylate
para-aminosalicylic acid
aminosalicylate potassium
aminosalicylate sodium
teebacin

An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.

Molecular weight: 153.14
Formula: C7H7NO3
CLOGP: 1.06
LIPINSKI: 0
HAC: 4
HDO: 3
TPSA: 83.55
ALOGS: -1.11
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
12	g	O
14	g	O
14	g	P
15	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	1.69 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1306.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
March 8, 1950	FDA	CONSOLIDATED MIDLAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Colitis ulcerative	366.42	20.24	113	3952	25978	63458979
Frequent bowel movements	156.87	20.24	58	4007	22964	63461993
Off label use	103.98	20.24	167	3898	674295	62810662
Lipase increased	102.17	20.24	34	4031	9866	63475091
Pancreatitis	97.39	20.24	52	4013	49003	63435954
Drug resistance	97.17	20.24	41	4024	22892	63462065
Electrocardiogram QT prolonged	93.28	20.24	54	4011	59476	63425481
Rectal haemorrhage	75.52	20.24	44	4021	48986	63435971
Diarrhoea haemorrhagic	58.66	20.24	22	4043	9020	63475937
Mucous stools	57.77	20.24	18	4047	4230	63480727
Haematochezia	52.21	20.24	36	4029	53508	63431449
Anaemia	49.41	20.24	76	3989	293354	63191603
Therapeutic reaction time decreased	45.03	20.24	13	4052	2357	63482600
Polyneuropathy	39.21	20.24	19	4046	14570	63470387
Herbal toxicity	33.42	20.24	5	4060	31	63484926
Proctitis	30.84	20.24	12	4053	5429	63479528
Myelosuppression	30.57	20.24	19	4046	23684	63461273
Neuropathy peripheral	30.55	20.24	37	4028	113630	63371327
Porphyria acute	29.40	20.24	8	4057	1169	63483788
Purulent discharge	28.89	20.24	11	4054	4695	63480262
Intentional product use issue	28.62	20.24	38	4027	127854	63357103
Skin warm	27.27	20.24	11	4054	5465	63479492
Immune reconstitution inflammatory syndrome associated tuberculosis	27.24	20.24	6	4059	364	63484593
Subcutaneous abscess	27.04	20.24	11	4054	5585	63479372
Flatulence	26.21	20.24	20	4045	34682	63450275
Abdominal tenderness	26.14	20.24	12	4053	8154	63476803
Hyperalbuminaemia	25.73	20.24	4	4061	33	63484924
Meningitis tuberculous	24.42	20.24	6	4059	587	63484370
Arthropod bite	23.29	20.24	11	4054	7967	63476990
Multiple-drug resistance	21.07	20.24	9	4056	5161	63479796
Anal incontinence	20.39	20.24	12	4053	13564	63471393

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	270.89	31.27	112	3182	40840	34912797
Colitis ulcerative	245.61	31.27	82	3212	16438	34937199
Off label use	174.53	31.27	204	3090	419320	34534317
Hepatotoxicity	132.39	31.27	56	3238	21429	34932208
Frequent bowel movements	123.05	31.27	46	3248	12741	34940896
Intentional product use issue	107.57	31.27	68	3226	59748	34893889
Drug resistance	97.70	31.27	48	3246	25879	34927758
Tuberculosis	68.65	31.27	27	3267	8550	34945087
Haematochezia	66.77	31.27	46	3248	46488	34907149
Steroid dependence	64.42	31.27	17	3277	1500	34952137
Impaired quality of life	63.57	31.27	23	3271	5795	34947842
Neuropathy peripheral	56.40	31.27	53	3241	83210	34870427
Condition aggravated	51.63	31.27	76	3218	192120	34761517
Bronchiectasis	48.74	31.27	22	3272	9779	34943858
Myelosuppression	47.80	31.27	27	3267	19238	34934399
Inappropriate schedule of product administration	46.72	31.27	42	3252	62254	34891383
Impaired work ability	45.75	31.27	19	3275	6911	34946726
Polyneuropathy	42.79	31.27	23	3271	14873	34938764
Rectal haemorrhage	40.16	31.27	32	3262	40217	34913420
Product use in unapproved indication	39.76	31.27	52	3242	117447	34836190
Gastrointestinal inflammation	38.79	31.27	14	3280	3497	34950140
Blood pressure fluctuation	38.64	31.27	26	3268	25223	34928414
Faecal calprotectin increased	35.22	31.27	12	3282	2532	34951105
Benign soft tissue neoplasm	31.56	31.27	6	3288	116	34953521

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Colitis ulcerative	487.46	21.08	160	6454	34582	79703192
Electrocardiogram QT prolonged	351.37	21.08	164	6450	90222	79647552
Off label use	288.29	21.08	362	6252	906853	78830921
Drug resistance	177.41	21.08	81	6533	42132	79695642
Frequent bowel movements	174.22	21.08	72	6542	29467	79708307
Intentional product use issue	130.76	21.08	105	6509	152007	79585767
Hepatotoxicity	130.55	21.08	70	6544	51282	79686492
Haematochezia	93.84	21.08	69	6545	87576	79650198
Polyneuropathy	87.93	21.08	42	6572	24109	79713665
Neuropathy peripheral	83.81	21.08	79	6535	141226	79596548
Myelosuppression	78.09	21.08	46	6568	40250	79697524
Therapeutic reaction time decreased	73.53	21.08	22	6592	3479	79734295
Inappropriate schedule of product administration	61.29	21.08	65	6549	133563	79604211
Steroid dependence	57.29	21.08	17	6597	2613	79735161
Rectal haemorrhage	55.72	21.08	48	6566	76252	79661522
Tuberculosis	50.99	21.08	25	6589	15173	79722601
Anaemia	50.79	21.08	113	6501	444902	79292872
Condition aggravated	41.97	21.08	113	6501	501011	79236763
Faecal calprotectin increased	41.28	21.08	16	6598	5525	79732249
Product use in unapproved indication	41.02	21.08	74	6540	250285	79487489
Impaired quality of life	37.60	21.08	20	6594	14366	79723408
Bronchiectasis	34.28	21.08	22	6592	22364	79715410
Benign soft tissue neoplasm	31.85	21.08	6	6608	126	79737648
Blood pressure fluctuation	29.58	21.08	32	6582	67113	79670661
Toxic optic neuropathy	27.51	21.08	8	6606	1145	79736629
Meningitis tuberculous	27.17	21.08	8	6606	1197	79736577
Optic neuritis	27.06	21.08	14	6600	9506	79728268
Hypothyroidism	26.71	21.08	27	6587	52365	79685409
Weight decreased	26.61	21.08	77	6537	355121	79382653
Optic neuropathy	25.74	21.08	10	6604	3474	79734300
Porphyria acute	25.26	21.08	8	6606	1527	79736247
Herbal toxicity	25.15	21.08	4	6610	29	79737745
Gastrointestinal disorder	25.12	21.08	40	6574	122165	79615609
Fibroma	24.90	21.08	7	6607	888	79736886
Psychotic disorder	24.20	21.08	23	6591	41379	79696395
Hyperalbuminaemia	23.57	21.08	4	6610	45	79737729
Purulent discharge	23.49	21.08	11	6603	6028	79731746
Intracardiac mass	22.84	21.08	5	6609	226	79737548
Skin warm	22.51	21.08	11	6603	6621	79731153
Multiple-drug resistance	22.33	21.08	12	6602	8796	79728978
Impaired work ability	22.17	21.08	16	6598	19665	79718109
Mucous stools	21.94	21.08	10	6604	5152	79732622
Product use issue	21.32	21.08	51	6563	209771	79528003

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J04AA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Aminosalicylic acid and derivatives
ATC	J04AA02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Aminosalicylic acid and derivatives
ATC	J04AA03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Aminosalicylic acid and derivatives
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000995	Antitubercular Agents
CHEBI has role	CHEBI:33231	antitubercular agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute tuberculosis	indication	25629007
Pulmonary tuberculosis	indication	154283005	DOID:2957
Crohn's disease	off-label use	34000006
Ulcerative colitis	off-label use	64766004	DOID:8577
Goiter	contraindication	3716002	DOID:12176
Peptic ulcer	contraindication	13200003	DOID:750
Hypokalemia	contraindication	43339004
Crystalluria	contraindication	46784006
Chronic heart failure	contraindication	48447003
Acidosis	contraindication	51387008
Duodenal ulcer disease	contraindication	51868009	DOID:1724
Kidney disease	contraindication	90708001	DOID:557
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Cobalamin deficiency	contraindication	190634004
Disease of liver	contraindication	235856003	DOID:409
Gastric ulcer	contraindication	397825006	DOID:10808

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.71	acidic
pKa2	12.94	acidic
pKa3	2.33	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cyclooxygenase	Enzyme	P23219 P35354	PGH1_HUMAN PGH2_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Tyrosine-protein phosphatase non-receptor type 1	Enzyme	P18031	PTN1_HUMAN		Kd	2.92	CHEMBL
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase	Kinase		HPPK_MYCTO				WOMBAT-PK

External reference:

ID	Source
4018852	VUID
N0000180192	NUI
D00162	KEGG_DRUG
133-09-5	SECONDARY_CAS_RN
4018852	VANDF
4018919	VANDF
C0030125	UMLSCUI
CHEBI:27565	CHEBI
CHEMBL1169	ChEMBL_ID
CHEMBL1200584	ChEMBL_ID
CHEMBL2105983	ChEMBL_ID
D010131	MESH_DESCRIPTOR_UI
DB00233	DRUGBANK_ID
6018-19-5	SECONDARY_CAS_RN
5B2658E0N2	UNII
4649	PUBCHEM_CID
7833	RXNORM
10002	MMSL
4176	MMSL
d01099	MMSL
d04226	MMSL
002845	NDDF
002846	NDDF
002847	NDDF
20231007	SNOMEDCT_US
255666002	SNOMEDCT_US
417238004	SNOMEDCT_US
65222005	SNOMEDCT_US
BHA	PDB_CHEM_ID
CHEMBL2096646	ChEMBL_ID
CHEMBL1200966	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Paser	HUMAN PRESCRIPTION DRUG LABEL	1	49938-107	GRANULE, DELAYED RELEASE	4 g	ORAL	ANDA	21 sections